Evaluation of the New Variant 501Y.V2 of COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-01

Study Completion Date

2021-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In January 2021, the incidence of COVID-19-and its mortality started rising for the third time in France. This rise may associate with three emerging variants, namely, V1, V2, and V3, which are the 20I/501Y.V1 ("English"), 20H/501Y.V2 ("South African"), and 20J/501Y.V3 ("Brazilian") variants, respectively. V1 was recently suggested to increase mortality in people in the United Kingdom who tested positive for COVID-19 on community screening. Very little is known about V2 infection, including its outcomes relative to other strains. In early 2021, V2 spread to the Grand-Est region (northeastern France). Here, the investigators aimed to report mortality data of patients admitted in ICU between February and April 2021 in 3 hospitals in Grand-Est: Metz, Thionville and Nancy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Severity of the New UK SARS-Cov2 Variant in COVID-19 Infection

NCT04863547

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

UNKNOWN

COVID-19 Seroprevalence in Pregnant Women and Blood Donors

NCT04893057

COVID-19 Respiratory Infection

COMPLETED

Evaluation of the Detection Performance of the N Antigenemia of SARS-CoV-2 in the General Population for the Diagnosis and Screening of COVID-19

NCT05092607

Respiratory Viral Infection

UNKNOWN NA

CoViD-19 Patient in Reims University Hospital in March to April 2020

NCT04553575

Coronavirus Infections

COMPLETED

Study of the Incidence of SARS-CoV-2 Infection (COVID-19)

NCT04429594

Coronavirus Infections

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Admission in ICU in February, March or April 2021
* Patient with a SARS-CoV-2 positive polymerase-chain reaction test
* Patient with 20I/501Y.V1 ("English") or 20H/501Y.V2 ("South African") SARS-CoV-2 variants